In the fight against cancer, it’s boom times for radiopharmaceuticals

STAT | November 8th, 2023

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review | October 19th, 2023

Developing Best-in-Class Radiopharmaceuticals for Cancer Patients

Rx for Biotech | September 19th, 2023

Health Innovators- Dr. Jack Hoppin and Dr. John Babich (follow-up)

Pharmaphorum | August 17th, 2023

Radiopharmaceuticals for cancer: Making radiation precise

BioPharma Dive | August 15th, 2023

Ratio Therapeutics announces first patient dosed in FAP-targeted radiopharmaceutical study

BioPharma Reporter | July 31st, 2023

Treating Cancer using Targeted Radiotherapeutics with Jack Hoppin and John Babich of Ratio Therapeutics

From Launch to Lab by Qualio | July 26th, 2023

Ratio: tuning the pharmakokinetics of radiotherapies

BioCentury | June 30th, 2023

The dawn of the interim CFO

CFO Dive | May 16th, 2023

Ratio Therapeutics unveils new research and development facility

BioPharma Reporter | May 15th, 2023

Radiopharmaceuticals on their way to becoming mainstream cancer therapies

BioWorld | April 3rd, 2023

FDA Guiding Industry to Optimize Cancer Drug Dosing in Precision Oncology Era

Precision Oncology News | March 28th, 2023

In releasing a draft guidance earlier this year on dose optimization for cancer therapies, the US Food and Drug Administration is steadily advancing its decades-long campaign to move the industry away from the default use of a maximum-tolerated dosing paradigm in clinical trials and toward a more patient-centered approach.

Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium and Macropa Platforms

SCRIP | March 10th, 2023

#325- Jack Hoppin and John Babich of Ratio Therapeutics

Slice of Healthcare | March 6th, 2023

Ratio Therapeutics CFO gets due-diligence ready

CFO Dive | February 9th, 2023

Ratio Therapeutics Raises $20M in Series A Financing

Precision Oncology News | February 2nd, 2023

Tunable Radio Pharmaceuticals? The Founders of Ratio Therapeutics

BioTechIQ Podcast | Janurary 6th, 2023

Ratio Therapeutics CDO: “Part of Our Data Team’s Role is Being an Ambassador”

CDO Magazine | December 12th, 2022

Health Innovators- Dr. Jack Hoppin and Dr. John Babich

Pharmaphorum | December 9th, 2022

Building New Solutions For 2023 In Manufacturing And Supply Chain

Life Science Leader | December 1st, 2022

Ratio Therapeutics: Math Meets Medicine in the Design of Radiotherapies

Hopkins Biotech Podcast | November 20th, 2022

Ratio Therapeutics CDO: It’s Rewarding to Ingest Disparate Data in a Structured Way

CDO Magazine | November 1st, 2022

Ratio Therapeutics with FAPI and more Audio

The Nuclear Medicine and Molecular Medicine Podcast | October 18th, 2022

Targeting and Deploying Optimum Radiopharmaceuticals to Treat Cancer with Jack Hoppin and John Babich Ratio Therapeutics

The Empowered Patient Podcast | September 27th, 2022

Ratio Therapeutics emerges with $20M financing, taking mathematical approach to radiopharmaceuticals

BioWorld | June 20th, 2022

The Petri Dish: Amylyx, Alnylam net drug approvals

Boston Business Journal | June 16th, 2022

Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals

Precision Oncology News | June 16th, 2022